{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T19:41:15Z","timestamp":1780688475237,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,24]]},"DOI":"10.7759\/cureus.70114","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T19:32:36Z","timestamp":1727206356000},"source":"Crossref","is-referenced-by-count":3,"title":["Oral Liposomal Iron Versus Injectable Iron Sucrose for Anemia Treatment in Non-dialysis Chronic Kidney Disease Patients: A Non-inferiority Study"],"prefix":"10.7759","author":[{"given":"Soufiane","family":"Bengelloun Zahr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yassine","family":"Allata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouna","family":"El Mansoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basmat Amal","family":"Chouhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Kabbali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghita","family":"El Bardai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarik","family":"Sqalli Houssaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Dr\u00fceke TB","year":"2006","unstructured":"Dr\u00fceke TB, Locatelli F, Clyne N, et al.. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006, 355:2071-84. 10.1056\/NEJMoa062276","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1182494","article-title":"An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease","volume":"15","author":"Del Vecchio L","year":"2016","unstructured":"Del Vecchio L, Locatelli F. An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease. Expert Opin Drug Saf. 2016, 15:1021-30. 10.1080\/14740338.2016.1182494","journal-title":"Expert Opin Drug Saf"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2020.08.002","article-title":"Erythropoiesis-stimulating agent hyporesponsiveness and adverse outcomes: guilty as charged?","volume":"2","author":"Wish JB","year":"2020","unstructured":"Wish JB. Erythropoiesis-stimulating agent hyporesponsiveness and adverse outcomes: guilty as charged?. Kidney Med. 2020, 2:526-8. 10.1016\/j.xkme.2020.08.002","journal-title":"Kidney Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2012.34","article-title":"Chapter 2: Use of iron to treat anemia in CKD","volume":"2","year":"2012","unstructured":"Chapter 2. Use of iron to treat anemia in CKD. Kidney Int Suppl. 2012, 2:292-8. 10.1038\/kisup.2012.34","journal-title":"Kidney Int Suppl"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007101156","article-title":"Ferumoxytol for treating iron deficiency anemia in CKD","volume":"19","author":"Spinowitz BS","year":"2008","unstructured":"Spinowitz BS, Kausz AT, Baptista J, et al.. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol. 2008, 19:1599-605. 10.1681\/ASN.2007101156","journal-title":"J Am Soc Nephrol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00758.x","article-title":"A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD","volume":"68","author":"Van Wyck DB","year":"2005","unstructured":"Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005, 68:2846-56. 10.1111\/j.1523-1755.2005.00758.x","journal-title":"Kidney Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P466","article-title":"A comparative look at the safety profiles of intravenous iron products used in the hemodialysis population","volume":"45","author":"Coppol E","year":"2011","unstructured":"Coppol E, Shelly J, Cheng S, Kaakeh Y, Shepler B. A comparative look at the safety profiles of intravenous iron products used in the hemodialysis population. Ann Pharmacother. 2011, 45:241-7. 10.1345\/aph.1P466","journal-title":"Ann Pharmacother"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-10-6","article-title":"The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data","volume":"10","author":"Pollak VE","year":"2009","unstructured":"Pollak VE, Lorch JA, Shukla R, Satwah S. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data. BMC Nephrol. 2009, 10:6. 10.1186\/1471-2369-10-6","journal-title":"BMC Nephrol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4140\/tcp.n.2007.230","article-title":"The safety of intravenous iron sucrose use in the elderly patient","volume":"22","author":"Reed J","year":"2007","unstructured":"Reed J, Charytan C, Yee J. The safety of intravenous iron sucrose use in the elderly patient. Consult Pharm. 2007, 22:230-8. 10.4140\/tcp.n.2007.230","journal-title":"Consult Pharm"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.05.020","article-title":"Treatment of iron deficiency anemia in CKD and end-stage kidney disease","volume":"6","author":"Guti\u00e9rrez OM","year":"2021","unstructured":"Guti\u00e9rrez OM. Treatment of iron deficiency anemia in CKD and end-stage kidney disease. Kidney Int Rep. 2021, 6:2261-9. 10.1016\/j.ekir.2021.05.020","journal-title":"Kidney Int Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfz091","article-title":"Anemia and iron deficiency among chronic kidney disease Stages 3-5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated","volume":"13","author":"Wong MM","year":"2020","unstructured":"Wong MM, Tu C, Li Y, et al.. Anemia and iron deficiency among chronic kidney disease Stages 3-5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated. Clin Kidney J. 2020, 13:613-24. 10.1093\/ckj\/sfz091","journal-title":"Clin Kidney J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5581\/1516-8484.20110119","article-title":"Efficacy and safety of intravenous iron sucrose in treating adults with iron deficiency anemia","volume":"33","author":"Can\u00e7ado RD","year":"2011","unstructured":"Can\u00e7ado RD, de Figueiredo PO, Olivato MC, Chiattone CS. Efficacy and safety of intravenous iron sucrose in treating adults with iron deficiency anemia. Rev Bras Hematol Hemoter. 2011, 33:439-43. 10.5581\/1516-8484.20110119","journal-title":"Rev Bras Hematol Hemoter"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2021.04.042","article-title":"Safety and efficacy of intravenous ferric derisomaltose compared to iron sucrose for iron deficiency anemia in patients with chronic kidney disease with and without heart failure","volume":"152","author":"Ambrosy AP","year":"2021","unstructured":"Ambrosy AP, von Haehling S, Kalra PR, Court E, Bhandari S, McDonagh T, Cleland JG. Safety and efficacy of intravenous ferric derisomaltose compared to iron sucrose for iron deficiency anemia in patients with chronic kidney disease with and without heart failure. Am J Cardiol. 2021, 152:138-45. 10.1016\/j.amjcard.2021.04.042","journal-title":"Am J Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfv142","article-title":"Safety concerns about intravenous iron therapy in patients with chronic kidney disease","volume":"9","author":"Del Vecchio L","year":"2016","unstructured":"Del Vecchio L, Longhi S, Locatelli F. Safety concerns about intravenous iron therapy in patients with chronic kidney disease. Clin Kidney J. 2016, 9:260-7. 10.1093\/ckj\/sfv142","journal-title":"Clin Kidney J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2019.05.002","article-title":"Novel oral iron therapies for iron deficiency anemia in chronic kidney disease","volume":"26","author":"Pergola PE","year":"2019","unstructured":"Pergola PE, Fishbane S, Ganz T. Novel oral iron therapies for iron deficiency anemia in chronic kidney disease. Adv Chronic Kidney Dis. 2019, 26:272-91. 10.1053\/j.ackd.2019.05.002","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25060","article-title":"Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial","volume":"93","author":"Adkinson NF","year":"2018","unstructured":"Adkinson NF, Strauss WE, Macdougall IC, et al.. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial. Am J Hematol. 2018, 93:683-90. 10.1002\/ajh.25060","journal-title":"Am J Hematol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.1999.055suppl.69061.x","article-title":"Strategies for iron supplementation: oral versus intravenous","volume":"69","author":"Macdougall IC","year":"1999","unstructured":"Macdougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int Suppl. 1999, 69:S61-6. 10.1046\/j.1523-1755.1999.055suppl.69061.x","journal-title":"Kidney Int Suppl"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.09.017","article-title":"Recent and emerging therapies for iron deficiency in anemia of CKD: a review","volume":"79","author":"Bazeley JW","year":"2022","unstructured":"Bazeley JW, Wish JB. Recent and emerging therapies for iron deficiency in anemia of CKD: a review. Am J Kidney Dis. 2022, 79:868-76. 10.1053\/j.ajkd.2021.09.017","journal-title":"Am J Kidney Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/nu16091255","article-title":"Efficacy and safety of oral supplementation with liposomal iron in non-dialysis chronic kidney disease patients with iron deficiency","volume":"16","author":"Cesarano D","year":"2024","unstructured":"Cesarano D, Borrelli S, Campilongo G, et al.. Efficacy and safety of oral supplementation with liposomal iron in non-dialysis chronic kidney disease patients with iron deficiency. Nutrients. 2024, 16:10.3390\/nu16091255","journal-title":"Nutrients"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2020.100862","article-title":"Intravenous iron supplementation therapy","volume":"75","author":"Schaefer B","year":"2020","unstructured":"Schaefer B, Meindl E, Wagner S, Tilg H, Zoller H. Intravenous iron supplementation therapy. Mol Aspects Med. 2020, 75:100862. 10.1016\/j.mam.2020.100862","journal-title":"Mol Aspects Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12400","article-title":"Differences between intravenous iron products: focus on treatment of iron deficiency in chronic heart failure patients","volume":"6","author":"Martin-Malo A","year":"2019","unstructured":"Martin-Malo A, Borchard G, Fl\u00fchmann B, Mori C, Silverberg D, Jankowska EA. Differences between intravenous iron products: focus on treatment of iron deficiency in chronic heart failure patients. ESC Heart Fail. 2019, 6:241-53. 10.1002\/ehf2.12400","journal-title":"ESC Heart Fail"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.4488","article-title":"Analysis of adverse events and intravenous iron infusion formulations in adults with and without prior infusion reactions","volume":"5","author":"Arastu AH","year":"2022","unstructured":"Arastu AH, Elstrott BK, Martens KL, et al.. Analysis of adverse events and intravenous iron infusion formulations in adults with and without prior infusion reactions. JAMA Netw Open. 2022, 5:e224488. 10.1001\/jamanetworkopen.2022.4488","journal-title":"JAMA Netw Open"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics3010012","article-title":"The pharmacokinetics and pharmacodynamics of iron preparations","volume":"3","author":"Geisser P","year":"2011","unstructured":"Geisser P, Burckhardt S. The pharmacokinetics and pharmacodynamics of iron preparations. Pharmaceutics. 2011, 3:12-33. 10.3390\/pharmaceutics3010012","journal-title":"Pharmaceutics"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14310","article-title":"Intravenous iron infusion in patients with heart failure: a systematic review and study-level meta-analysis","volume":"10","author":"Salah HM","year":"2023","unstructured":"Salah HM, Savarese G, Rosano GM, Ambrosy AP, Mentz RJ, Fudim M. Intravenous iron infusion in patients with heart failure: a systematic review and study-level meta-analysis. ESC Heart Fail. 2023, 10:1473-80. 10.1002\/ehf2.14310","journal-title":"ESC Heart Fail"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01323-z","article-title":"Iron sucrose: a wealth of experience in treating iron deficiency","volume":"37","author":"Macdougall IC","year":"2020","unstructured":"Macdougall IC, Comin-Colet J, Breymann C, Spahn DR, Koutroubakis IE. Iron sucrose: a wealth of experience in treating iron deficiency. Adv Ther. 2020, 37:1960-2002. 10.1007\/s12325-020-01323-z","journal-title":"Adv Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfu357","article-title":"Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial","volume":"30","author":"Pisani A","year":"2015","unstructured":"Pisani A, Riccio E, Sabbatini M, Andreucci M, Del Rio A, Visciano B. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrol Dial Transplant. 2015, 30:645-52. 10.1093\/ndt\/gfu357","journal-title":"Nephrol Dial Transplant"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq613","article-title":"A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients","volume":"26","author":"Qunibi WY","year":"2011","unstructured":"Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant. 2011, 26:1599-607. 10.1093\/ndt\/gfq613","journal-title":"Nephrol Dial Transplant"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27529","article-title":"Efficacy of oral versus injectable iron in patients with chronic kidney disease: a two-year cross-sectional study conducted at a rural teaching hospital","volume":"14","author":"Agrawal S","year":"2022","unstructured":"Agrawal S, Sonawane S, Kumar S, et al.. Efficacy of oral versus injectable iron in patients with chronic kidney disease: a two-year cross-sectional study conducted at a rural teaching hospital. Cureus. 2022, 14:e27529. 10.7759\/cureus.27529","journal-title":"Cureus"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1159\/000085049","article-title":"Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis","volume":"100","author":"Charytan C","year":"2005","unstructured":"Charytan C, Qunibi W, Bailie GR. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005, 100:c55-62. 10.1159\/000085049","journal-title":"Nephron Clin Pract"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.11.002","article-title":"The impact of intravenous iron on renal injury and function markers in patients with chronic kidney disease and iron deficiency without anemia","volume":"7","author":"Kassianides X","year":"2022","unstructured":"Kassianides X, Hazara AM, Macdougall IC, Kalra PA, Bhandari S. The impact of intravenous iron on renal injury and function markers in patients with chronic kidney disease and iron deficiency without anemia. Kidney Int Rep. 2022, 7:322-6. 10.1016\/j.ekir.2021.11.002","journal-title":"Kidney Int Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/280098-oral-liposomal-iron-versus-injectable-iron-sucrose-for-anemia-treatment-in-non-dialysis-chronic-kidney-disease-patients-a-non-inferiority-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T19:32:38Z","timestamp":1727206358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/280098-oral-liposomal-iron-versus-injectable-iron-sucrose-for-anemia-treatment-in-non-dialysis-chronic-kidney-disease-patients-a-non-inferiority-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.70114","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,24]]}}}